• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Risk of New-onset Stroke in Patients with Type 2 Diabetes with Chronic Kidney Disease on Sodium-glucose Co-transporter-2 Inhibitor Users
This study aimed to examine the association between the use of SGLT2 inhibitors and NOS risk in patients with T2D and CKD. We conducted a nationwide retrospective cohort study using data from the Taiwan Health Insurance Review and Assessment Service database for the years 2004 to 2019. The primary outcome was the risk of incident stroke, which was estimated using hazard ratios (HRs) and 95% confidence intervals (CIs). We used multiple Cox regression modeling to analyze the association between SGLT2 inhibitor use and the risk of stroke in patients with T2D and CKD. In a cohort of 113,710 patients with T2D and CKD who were u...
Source: Translational Stroke Research - July 14, 2023 Category: Neurology Source Type: research

Effect of SGLT2 Inhibitors on Risk of Stroke in Diabetes: A Meta-Analysis
Conclusions: In summary, this meta-analysis indicated that the use of SGLT2 inhibitors did not decrease the risk of stroke. And for some T2DM patients with high-risk factor of stroke, SGLT2 inhibitors therapy may be more suitable compared to some oGLD such as dipeptidyl peptidase-4 inhibitors. The results of this meta-analysis are necessary to be confirmed with further studies and clinical trials.Cerebrovasc Dis
Source: Cerebrovascular Diseases - January 31, 2022 Category: Neurology Source Type: research

Sodium-Glucose Co-Transporter-2 Inhibitors Decrease the Odds for Atrial Fibrillation in Subjects with Heart Failure
Ong et al. have shown in their very informative, recently published meta-analysis that sodium-glucose co-transporter-2 (SGLT-2) inhibitors result in a significant decrease in the odds for atrial fibrillation (AF) regardless of status of diabetes mellitus or cardiovascular disease at baseline.1 However, the authors failed to show that this effect is sustained in subjects with heart failure (HF).1
Source: Journal of Stroke and Cerebrovascular Diseases - December 22, 2021 Category: Neurology Authors: Dimitrios Patoulias, Christodoulos Papadopoulos, Michael Doumas Tags: Letter to the Editor Source Type: research

Effects of Sodium/Glucose Cotransporter Inhibitors on Atrial Fibrillation and Stroke: A Meta-Analysis
Globally, the number of people estimated to have diabetes mellitus (DM) in 2019 was 463 million, and the estimated number is expected to rise to 578 million people by 2030.1 DM is also associated with an increased risk of atrial fibrillation (AF), 2 and has shown to be an independent risk factor for stroke in patients with AF.3 A meta-analysis of 102 studies further showed that patients with diabetes have a higher risk of all subtypes of stroke (ischemic, hemorrhagic and unclassified stroke).4 This has generated great interest in anti-hyperglycemic agents and their ability to reduce the cardiovascular complications of diabetes.
Source: Journal of Stroke and Cerebrovascular Diseases - October 22, 2021 Category: Neurology Authors: How Ting Ong, Yao Hao Teo, Yao Neng Teo, Nicholas LX Syn, Caitlin Fern Wee, Shariel Leong, Alicia Swee Yan Yip, Ray Meng See, Adriel Zhi Hen Ting, Alys ZQ Chia, Alex Jia Yang Cheong, Benjamin Yong-Qiang Tan, Jamie Sin-Ying Ho, Leonard Leong-Litt Yeo, Aloy Source Type: research

Do all gliflozins reduce stroke in patients with type 2 diabetes mellitus and impaired renal function?
We have read with great interest a study of meta-analysis1 recently published in Journal of Stroke and Cerebrovascular Diseases. In that study1 Barkas and colleagues drew their main conclusion that sodium-glucose transporter 2 (SGLT2) inhibitors reduce the risk of total stroke in patients with type 2 diabetes mellitus (T2DM) and impaired renal function (IRF), which was based on the result of meta-analysis on the outcome of total stroke (including ischemic and hemorrhagic stroke) in the subgroup of patients with T2DM and IRF (Fig.
Source: Journal of Stroke and Cerebrovascular Diseases - April 17, 2021 Category: Neurology Authors: Li-Min Zhao, Liang-Liang Ding, Ze-Lin Zhan, Mei Qiu Tags: Letter to the Editor Source Type: research

Predictors of Survival in Chronic Hemodialysis Patients: A 10-Year Longitudinal Follow-Up Analysis
Conclusion: In chronic hemodialysis patients, targets to improve the short-term prognosis and long-term prognosis are not equivalent. Hyperphosphatemia was a significant risk factor for the all-cause mortality among patients with normal serum albumin levels but not among patients with compromised albumin levels.Am J Nephrol
Source: American Journal of Nephrology - March 23, 2021 Category: Neurology Source Type: research

Sodium-Glucose Cotransporter-2 Inhibitors and Protection Against stroke in Patients with type 2 Diabetes and Impaired Renal Function: A Systematic Review and Meta-Analysis
It is well established that diabetes mellitus type 2 (T2DM) is associated with increased risk of cardiovascular disease, including ischemic stroke. Among past antidiabetic agents, only pioglitazone and glucagon-like peptide 1 receptor agonists (GLP-1RA) have been shown to decrease the risk of stroke.1-5 Similarly, sodium-glucose cotransporter-2 inhibitors (SGLT2i) were expected to reduce the risk of stroke, considering their blood pressure lowering and neuroprotective effects demonstrated by experimental studies.
Source: Journal of Stroke and Cerebrovascular Diseases - March 10, 2021 Category: Neurology Authors: Fotios Barkas, Sebastian Filippas Ntekouan, Evangelos Liberopoulos, Theodosios Filippatos, Haralampos Milionis Source Type: research

Determinants of Use of Long-term Continuous Electrocardiographic Monitoring for Acute Ischemic Stroke Patients without Atrial Fibrillation at Baseline.
CONCLUSIONS: When selecting the high-risk group of patients (with an NIHSS score > 12 and age > 64.5 years, or with an NIHSS score ≤ 12, age > 71.5 years, and triglyceride level ≤ 61.5 mg/dL) according to the CART model, the detection rate of paroxysmal AF was approximately double in the acute ischemic stroke patients without AF at baseline. PMID: 32324514 [PubMed - as supplied by publisher]
Source: Current Neurovascular Research - April 21, 2020 Category: Neurology Authors: Lee JD, Huang YC, Lee M, Lee TH, Kuo YW, Hu YH, Ovbiagele B Tags: Curr Neurovasc Res Source Type: research

Intravenous thrombolysis with tPA and cortical involvement increase the risk of early poststroke seizures: Results of a case–control study
This article is part of the Special Issue “Seizures & Stroke
Source: Epilepsy and Behavior - June 8, 2019 Category: Neurology Source Type: research

Intravenous thrombolysis with tPA and cortical involvement increase the risk of early poststroke seizures: Results of a case-control study.
This article is part of the Special Issue "Seizures & Stroke. PMID: 31182396 [PubMed - as supplied by publisher]
Source: Epilepsy and Behaviour - June 6, 2019 Category: Neurology Authors: Brigo F, Schneider M, Wagenpfeil G, Ragoschke-Schumm A, Fousse M, Holzhoffer C, Nardone R, Faßbender K, Lochner P Tags: Epilepsy Behav Source Type: research

Neuroprotective effects of protein tyrosine phosphatase 1B inhibitor on cerebral ischemia/reperfusion in mice.
In this study, we confirmed the ameliorative effects of KY-226 on ischemia/reperfusion (I/R) injury using a murine model of middle cerebral artery occlusion (MCAO). ICR mice were subjected to MCAO for 2 h followed by reperfusion. Although KY-226 permeability was poor through the blood-brain barrier (BBB) of normal mice, it could penetrate through the BBB of mice after I/R insult. Intraperitoneal KY-226 administration elicited dose-dependent reductions in infarcted brain areas and improved neurological deficits. The neuroprotective effects of KY-266 were obtained when administered within 0.5 h after reperfusion. KY-226 (10 ...
Source: Brain Research - April 26, 2018 Category: Neurology Authors: Sun M, Izumi H, Shinoda Y, Fukunaga K Tags: Brain Res Source Type: research

Which Patients With Ischemic Stroke and Insulin Resistance May Benefit From Pioglitazone?
The Insulin Resistance Intervention After Stroke (IRIS) trial has reported that treating insulin resistance with the peroxisome proliferator –activated receptor γ agonist pioglitazone hydrochloride reduced recurrent stroke or myocardial infarction (MI) by about one-fourth compared with placebo (pioglitazone, 9.0% vs placebo, 11.8%; hazard ratio [HR], 0.76; 95% CI, 0.62-0.93) in 3876 patients with recent (<6 months) ischemic stroke or transient ischemic attack and insulin resistance but without diabetes, heart failure, or bladder cancer. Pioglitazone was also associated with less incident diabetes vs placebo (3.8% vs ...
Source: JAMA Neurology - November 1, 2017 Category: Neurology Source Type: research

Serum Potassium Is Positively Associated With Stroke and Mortality in the Large, Population-Based Malmo Preventive Proȷect Cohort Clinical Sciences
Background and Purpose—Low serum potassium is associated with stroke in populations with cardiovascular disease, hypertension, and diabetes mellitus but has not been studied in a mainly healthy population. We aimed to study the relation between serum potassium and incident stroke and mortality in the Malmö Preventive Project, a large cohort with screening in early mid-life and follow-up>25 years.Methods—Serum potassium measurements and covariates were available in 21 353 individuals (79% men, mean age 44 years). Mean follow-up time was 26.9 years for stroke analyses and 29.3 years for mortality analyses. There were ...
Source: Stroke - October 23, 2017 Category: Neurology Authors: Linda S. Johnson, Nick Mattsson, Ahmad Saȷadieh, Per Wollmer, Martin Soderholm Tags: Diet and Nutrition, Epidemiology, Lifestyle, Primary Prevention, Risk Factors Original Contributions Source Type: research

Which Patients With Ischemic Stroke and Insulin Resistance May Benefit From Pioglitazone?
The Insulin Resistance Intervention After Stroke (IRIS) trial has reported that treating insulin resistance with the peroxisome proliferator –activated receptor γ agonist pioglitazone hydrochloride reduced recurrent stroke or myocardial infarction (MI) by about one-fourth compared with placebo (pioglitazone, 9.0% vs placebo, 11.8%; hazard ratio [HR], 0.76; 95% CI, 0.62-0.93) in 3876 patients with recent (<6 months) ischemic stroke or transient ischemic attack and insulin resistance but without diabetes, heart failure, or bladder cancer. Pioglitazone was also associated with less incident diabetes vs placebo (3.8% vs ...
Source: JAMA Neurology - September 18, 2017 Category: Neurology Source Type: research